<DOC>
	<DOCNO>NCT01549119</DOCNO>
	<brief_summary>The purpose trial evaluate safety immunogenicity therapeutic vaccine candidate VAC-3S HIV-1 infect patient AntiRetroviral Therapy ( ART ) undetectable viral load .</brief_summary>
	<brief_title>Phase I/IIa Dose-escalation Clinical Study VAC-3S</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 infect patient Age 18 55 year ART ( AntiRetroviral Therapy ) initiation 1 year ago Plasma HIV RNA 50 copy per ml three sequential occasion include V1 past 12 month CD4 T cell count equal 200 cell per mm3 , Nadir CD4 T cell count equal 100 cell per mm3 , Contraception woman childbearing potential Any ART change within month precede screen . Chronic active liver disease , HIVHepatitis Coinfection . Immunotherapy past year , immunosuppressive treatment within past month . History autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>active immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>virulence</keyword>
	<keyword>innate immunity</keyword>
	<keyword>NK cell</keyword>
</DOC>